An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective

Expert Opinion on Pharmacotherapy
Yoshifumi Saisho

Abstract

Recent advances in anti-diabetic medications and glucose monitoring have led to a paradigm shift in diabetes care. Newer anti-diabetic medications such as DPP-4 inhibitors, GLP-1 receptor agonists (GLP-1RAs), and SGLT2 inhibitors have enabled optimal glycemic control to be achieved without increasing the risk of hypoglycemia and weight gain. Treatment with GLP-1RAs and SGLT2 inhibitors has been demonstrated to improve cardiorenal outcomes, positioning these agents as the mainstay of treatment for patients with type 2 diabetes (T2DM). The development of these newer agents has also prompted a paradigm shift in the concept of T2DM, highlighting the importance of beta cell dysfunction in the pathophysiology of T2DM. Recent advances in pharmacotherapy for diabetes are summarized with a focus on the role of incretin-based drugs and SGLT2 inhibitors. The importance of a paradigm shift from a glucose-centric to a beta cell-centric concept of T2DM is also discussed, given from an Asian perspective. Management of T2DM including lifestyle modification as well as pharmacotherapy should be focused on reducing beta cell workload, to preserve functional beta cell mass. A paradigm shift from a glucose-centric to a beta cell-centric concept of ...Continue Reading

Associated Clinical Trials

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Dec 28, 2002·Diabetes·Alexandra E ButlerPeter C Butler
Jan 31, 2003·The New England Journal of Medicine·Peter GaedeOluf Pedersen
May 3, 2003·The Journal of Clinical Endocrinology and Metabolism·Kun Ho YoonSusan Bonner-Weir
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Feb 8, 2008·The New England Journal of Medicine·Peter GaedeOluf Pedersen
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Oct 18, 2008·Diabetes, Obesity & Metabolism·J RahierJ C Henquin
May 12, 2009·Metabolism: Clinical and Experimental·Koichiro AzumaUNKNOWN ERA JUMP study group
Feb 16, 2010·European Heart Journal·Steven E Nissen
Mar 17, 2010·The New England Journal of Medicine·Rury R HolmanRobert M Califf
Apr 7, 2010·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Parminder S ChaggarSimon G Williams
May 29, 2010·Diabetes Care·Cyrus V DesouzaVivian Fonseca
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Jun 7, 2011·The American Journal of Pathology·Catherine A JurgensRebecca L Hull
Jun 24, 2011·The Journal of Clinical Endocrinology and Metabolism·Ralph A DeFronzo, Muhammad A Abdul-Ghani
Jun 15, 2013·The Journal of Clinical Endocrinology and Metabolism·Kinsei KouHiroshi Itoh
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Dec 21, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Jan 15, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·I TeraguchiT Akasaka
Feb 11, 2014·Diabetes Research and Clinical Practice
Oct 19, 2010·Journal of Diabetes Investigation·Yutaka SeinoKohjiro Ueki
May 21, 2014·Journal of Diabetes Investigation·Hiroki MizukamiSoroku Yagihashi
Aug 15, 2014·The Journal of Clinical Endocrinology and Metabolism·Jonas B MøllerClaudio Cobelli

❮ Previous
Next ❯

Citations

Jun 27, 2020·Diabetes/metabolism Research and Reviews·Yue ZhouYangang Wang
Mar 25, 2021·Pharmacogenomics and Personalized Medicine·Ranjit UnnikrishnanViswanathan Mohan
Apr 4, 2021·International Journal of Molecular Sciences·Hideaki KanetoKohei Kaku
Aug 19, 2021·Journal of the Endocrine Society·Hironobu SasakiHiroshi Itoh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Yehuda Handelsman
© 2022 Meta ULC. All rights reserved